CorMedix Inc. (CRMD) Financial Statements
CorMedix Inc. (CRMD) reported trailing twelve-month revenue of $462.2M (up 280.5% year on year) and net income of $187.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $250.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CRMDCorMedix Inc.Follow CRMD — free
—
Price chart with a free account
- Market cap
- 611.9M
- P/E TTM
- 3.8
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0 | 0.2 | 0.2 | 0.2 | 0.3 | 0.4 | 0.3 | 0.2 | 0.2 | 0.1 | 43.5 | 311.7 | 462.2 | |
| Gross profit | -0.2 | -0.3 | -0.1 | -0.1 | 0.2 | 0.0 | -0.1 | 0.0 | 0.0 | 0.1 | 40.3 | 275.7 | 382.6 | |
| Research & development | 1.2 | 1.3 | 6.3 | 15.7 | 24.5 | 18.8 | 11.1 | 13.4 | 13.1 | 10.7 | 3.9 | 19.3 | 27.6 | |
| Operating income | -4.9 | -8.9 | -16.7 | -24.8 | -32.9 | -26.9 | -21.0 | -27.2 | -29.4 | -30.6 | -22.4 | 150.1 | 217.0 | |
| Pre-tax income | -9.1 | -20.5 | -18.2 | -24.6 | -33.0 | -26.8 | -21.5 | -27.2 | -29.5 | -30.3 | -19.3 | 150.0 | 203.4 | |
| Income tax | 0.0 | — | — | — | — | — | -5.1 | -5.2 | -1.3 | -0.6 | -1.4 | -13.0 | 16.2 | |
| Net income | -9.1 | -20.5 | -18.2 | -24.6 | -33.0 | -26.8 | -16.4 | -22.0 | -28.2 | -29.7 | -17.9 | 163.1 | 187.2 | |
| Diluted EPS ($) | -0.69 | -0.96 | -0.58 | -0.65 | -0.60 | -1.51 | -1.80 | -0.77 | -0.75 | -0.74 | -0.30 | 2.04 | 2.06 | |
| Diluted shares (mn) | — | — | — | — | — | — | — | — | — | 40.3 | 58.9 | 80.3 | — |
USD millions · SEC XBRL
CorMedix Inc. — questions
- What is CorMedix Inc.'s revenue?
- $462.2M over the twelve months to 2026-06-30, up 280.5% year on year, from its 10-Q and 10-K filings.
- What is CorMedix Inc.'s net income?
- $187.2M over the twelve months to 2026-06-30.
- What is CorMedix Inc.'s free cash flow?
- $250.4M over the twelve months to 2026-06-30.
- What are CorMedix Inc.'s diluted earnings per share?
- $2.06 over the twelve months to 2026-06-30.
Every figure on this page comes from CorMedix Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.